Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) has been given a consensus rating of “Buy” by the six brokerages that are presently covering the company. One analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $10.00.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Eyegate Pharmaceuticals in a report on Tuesday, October 25th.

Shares of Eyegate Pharmaceuticals (NASDAQ:EYEG) traded down 8.11% during midday trading on Wednesday, reaching $1.70. 671,705 shares of the company’s stock were exchanged. The stock’s market cap is $16.29 million. The company’s 50-day moving average is $1.54 and its 200-day moving average is $2.15. Eyegate Pharmaceuticals has a one year low of $1.11 and a one year high of $5.10.

COPYRIGHT VIOLATION NOTICE: “Eyegate Pharmaceuticals Inc (EYEG) Given Consensus Recommendation of “Buy” by Brokerages” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2016/11/30/eyegate-pharmaceuticals-inc-eyeg-given-consensus-recommendation-of-buy-by-brokerages.html.

An institutional investor recently bought a new position in Eyegate Pharmaceuticals stock. Sabby Management LLC purchased a new position in shares of Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 386,940 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,002,000. Sabby Management LLC owned about 4.64% of Eyegate Pharmaceuticals at the end of the most recent reporting period.

Eyegate Pharmaceuticals Company Profile

Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.

5 Day Chart for NASDAQ:EYEG

Receive News & Stock Ratings for Eyegate Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.